Emyria Limited (ASX:EMD)

39.5¢

right-arrow Created with Sketch. -0.055 (-12.22%)
MCAP $108.3M
Last trade 16.10pm 03/12/2021 20mins delayed

Latest Announcements

01/12/2021EMDEmyria Limited
01/12/2021EMDEmyria Limited
01/12/2021EMDEmyria Limited
30/11/2021EMDEmyria Limited
29/11/2021EMDEmyria Limited
26/11/2021EMDEmyria Limited
26/11/2021EMDEmyria Limited

Company Overview

Emyria Limited is an Australia-based healthcare technology and clinical research company. The Company provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.

EMD in the news

Emyria (EMD) has successfully completed a $5 million share placement to Andrew…
Emyria (EMD) joins the Palantir’s Foundry Builders Program, giving it access to…
Emyria (EMD) says its first batch of MDMA have demonstrated excellent purity…

Search Previous Announcements